267 related articles for article (PubMed ID: 25627654)
1. Three steps to breaking immune tolerance to lymphoma: a microparticle approach.
Makkouk A; Joshi VB; Lemke CD; Wongrakpanich A; Olivier AK; Blackwell SE; Salem AK; Weiner GJ
Cancer Immunol Res; 2015 Apr; 3(4):389-98. PubMed ID: 25627654
[TBL] [Abstract][Full Text] [Related]
2. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.
Makkouk A; Joshi VB; Wongrakpanich A; Lemke CD; Gross BP; Salem AK; Weiner GJ
AAPS J; 2015 Jan; 17(1):184-93. PubMed ID: 25331103
[TBL] [Abstract][Full Text] [Related]
3. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
5. CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery.
Kheirolomoom A; Ingham ES; Mahakian LM; Tam SM; Silvestrini MT; Tumbale SK; Foiret J; Hubbard NE; Borowsky AD; Murphy WJ; Ferrara KW
J Control Release; 2015 Dec; 220(Pt A):253-264. PubMed ID: 26471394
[TBL] [Abstract][Full Text] [Related]
6. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
7. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
8. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
Marabelle A; Kohrt H; Sagiv-Barfi I; Ajami B; Axtell RC; Zhou G; Rajapaksa R; Green MR; Torchia J; Brody J; Luong R; Rosenblum MD; Steinman L; Levitsky HI; Tse V; Levy R
J Clin Invest; 2013 Jun; 123(6):2447-63. PubMed ID: 23728179
[TBL] [Abstract][Full Text] [Related]
9. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
10. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
12. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
[TBL] [Abstract][Full Text] [Related]
13. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
14. Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles.
Da Silva CG; Camps MGM; Li TMWY; Zerrillo L; Löwik CW; Ossendorp F; Cruz LJ
Theranostics; 2019; 9(22):6485-6500. PubMed ID: 31588231
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
16. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells.
Yang H; Yamazaki T; Pietrocola F; Zhou H; Zitvogel L; Ma Y; Kroemer G
Cancer Res; 2015 Sep; 75(18):3812-22. PubMed ID: 26208907
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice.
Hsu FT; Chen TC; Chuang HY; Chang YF; Hwang JJ
Oncotarget; 2015 Dec; 6(42):44134-50. PubMed ID: 26683520
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
20. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
